Back to top
more

CymaBay Therapeutics Inc. (CBAY)

(Delayed Data from NSDQ)

$13.12 USD

13.12
454,386

+0.67 (5.38%)

Updated May 3, 2019 04:00 PM ET

After-Market: $13.12 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics

The Zacks Analyst Blog Highlights: Aileron Therapeutics, Energy Focus, MicroVision, Mersana Therapeutics and CymaBay Therapeutics

Tirthankar Chakraborty headshot

5 Top Stocks Up 100%+ in May With More Room to Run

Reopening of the economy, vaccine hopes and stimulus measures helped Wall Street climb north in May and squash the old adage "sell in May and go away."

Is CymaBay Therapeutics (CBAY) Stock a Solid Choice Right Now?

CymaBay Therapeutics (CBAY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Do Options Traders Know Something About CymaBay Therapeutics (CBAY) Stock We Don't?

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

Generic Drugs Industry's Prospects Uncertain Amid Coronavirus

Stabilizing prices of generic drugs have led to recovery in the industry. New launches have also provided a boost. However, coronavirus crisis creates an uncertainty for the industry.

Is the Options Market Predicting a Spike in CymaBay Therapeutics (CBAY) Stock?

Investors need to pay close attention to CymaBay Therapeutics (CBAY) stock based on the movements in the options market lately.

CymaBay Therapeutics Enters Oversold Territory

CymaBay Therapeutics, Inc. (CBAY) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Gilead (GILD) Announces Top-Line Results From NASH Study

Gilead's (GILD) mid-stage study on combination and monotherapy investigational treatments for advanced fibrosis due to NASH fails to meet the primary endpoint.

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

The Zacks Analyst Blog Highlights: Intercept, CymaBay, Amgen, Global Blood Therapeutics and ChemoCentryx

Ekta Bagri headshot

NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

Key highlights of the past week include regulatory and pipeline updates.

Company News For Nov 26, 2019

Companies In The News Are:

Intercept's (ICPT) NDA for NASH Drug Gets Priority Review

Intercept (ICPT) obtains Priority Review for its NDA for OCA in the United States for the treatment of fibrosis due to NASH.

CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock

CymaBay Therapeutics (CBAY) needs investors to pay close attention to the stock based on moves in the options market lately.

New Strong Sell Stocks for August 2nd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

    New Strong Sell Stocks for July 26th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

      New Strong Sell Stocks for July 11th

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

        CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher

        CymaBay Therapeutics (CBAY) was a big mover last session, as the company saw its shares rise more than 11% on the day.

          Why CymaBay Therapeutics (CBAY) Might Surprise This Earnings Season

          CymaBay Therapeutics (CBAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.

            Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%

            Cymabay Therapeutics, Inc. (CBAY) moved big last session, as its shares rose over 6% on the day.

              Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options

              Investors need to pay close attention to Cymabay Therapeutics (CBAY) stock based on the movements in the options market lately.

                New Analyst Coverage Make These 5 Stocks Worth a Bet

                Most investors depend on analysts' research before taking decisions as they fear that lack of information might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive access to relevant data.

                  Will Cymabay Therapeutics (CBAY) Continue to Surge Higher?

                  As of late, it has definitely been a great time to be an investor in Cymabay Therapeutics, Inc. (CBAY)